A

Amgen

Biotech company creating biologic medicines

Strategic Sourcing Manager G&A and GCO Cross-Category

Full-TimeUpdated on 10/9/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person

About the job

Requirements
  • Proven strategic sourcing experience.
  • Strong supplier negotiation skills.
  • Experience with global procurement e-sourcing and contract lifecycle management tools such as SAP Ariba, Workday Strategic Sourcing, or Sirion Labs.
  • Proficiency in English.
  • A Bachelor's or Master's degree.
  • Eight to thirteen years of sourcing experience.
Responsibilities
  • Develop and execute global strategic sourcing initiatives to drive cost optimization, supplier performance, and risk management.
  • Lead supplier evaluations, negotiations, and end-to-end contract management to ensure best-in-class procurement practices.
  • Analyze large datasets related to procurement, supplier performance, and market trends to identify cost-saving opportunities and operational efficiencies.
  • Use data analytics tools to generate insights, create reports, and support strategic decision-making.
  • Collaborate with senior leadership and cross-functional teams to align sourcing strategies with business objectives; provide insights on market trends, supplier capabilities, and sourcing strategies, with accountability for outcomes.
  • Understand and influence business needs to proactively drive procurement strategies that support enterprise priorities.
  • Establish and manage key supplier relationships to enhance quality, innovation, and long-term value.
  • Ensure compliance with procurement policies, risk mitigation strategies, and sustainability initiatives.
  • Work with internal stakeholders and suppliers to support sourcing activities.
  • Work with the Procurement Commercial Category team to align sourcing execution with the overall procurement strategy.
  • Guide junior team members and contribute to continuous improvement.
  • Guide and facilitate collaboration across cross-functional teams and regional stakeholders to ensure sourcing execution meets organizational needs and is implemented effectively.
  • Ensure G&A and GCO cross-category procurement activities comply with regulatory, contractual, and operational risk requirements; partner with Legal, Compliance, Data Privacy, and Cybersecurity teams on risk mitigation and alignment with best practices.
  • Collaborate with Strategic Sourcing peers on the strategic approach to complex contract negotiations, providing guidance and ensuring appropriate processes and frameworks for RFPs, supplier evaluations, and contract development.
  • Activate procurement resources toward category priorities while managing stakeholder expectations.
  • Deliver results aligned with financial targets set by the Category Team and inform cost-savings forecasting through strategic sourcing.
Desired Qualifications
  • Demonstrated leadership in G&A and GCO cross-category sourcing, including vendor management, cost optimization, and performance measurement.
  • Experience negotiating with suppliers in the Life Sciences category, potentially including academic institutions.
  • Deep understanding of sourcing management principles, supplier relationship management, and contract lifecycle management.
  • Experience leading large cross-functional teams and managing complex global projects in a matrixed environment.
  • Strong financial, legal, and contractual fluency to navigate G&A and GCO cross-category service agreements and deliver business-aligned outcomes.
  • Ability to communicate sourcing strategies and influence senior stakeholders.
  • Familiarity with procurement platforms such as Ariba, ERP systems, and advanced analytics tools to support decision-making and process automation.
  • Understanding of regulatory landscapes and ability to navigate and manage compliance requirements.
  • Strong verbal and written communication skills.
  • Ability to work effectively with global, virtual teams.
  • Ability to navigate ambiguity.
  • High degree of initiative and self-motivation.
  • Ability to manage multiple priorities successfully.
  • Team-oriented approach focused on achieving team goals.
  • Influencing and change management skills.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $39.4 billion.
  • Imdelltra sales jumped 219% year over year in Q1 2026, signaling rapid launch traction.
  • Repatha sales rose 37% in Q2 2026, driven by expanding cardiology and primary-care adoption.

What critics are saying

  • Prolia and Enbrel face accelerating biosimilar erosion; Amgen expects continued sales declines through 2026.
  • Three distributors generated 77% of gross revenue in 2026, concentrating pricing leverage brutally.
  • MariTide failure would crater obesity optionality and expose Amgen's growth to aging franchises.

What makes Amgen unique

  • September 2026 Imdelltra-IMFINZI phase III hit overall survival in first-line ES-SCLC.
  • August 2026 Repatha reduced death risk in high-risk patients, strengthening Amgen's cardiovascular moat.
  • MariTide's monthly-or-less dosing and nine Phase III studies separate it from weekly GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.